GoAI
Get started
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.45

+$2.46 · +22.38%

Aug 21, 4:00 PM ET

Pre-market

$13.30

−$0.15 · -1.12%

Aug 24, 7:33 AM ET

ARCT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

26

Weakening

Sentiment

43

Mixed

Risk resilience

20

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Joseph E. Payne
Listed since
May 22, 2013
Employees
109

Market position

Day range

Current $13.45

52-week range

Current $13.45

Open
$11.13
Previous close
$10.99
Volume
2.86M
4.94× average
Average volume
578.16K
Average daily volume
Market cap
382.29M USD
Beta
2.27
Market reference 1
50-day average
$7.072
+90.19% above average
200-day average
$7.3884
+82.04% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-38.03M USD
P/E (TTM)
-4.04×
P/B (TTM)
2.23×
P/S (TTM)
16.06×
EV / EBITDA
0.61×
Earnings yield
-39.19%
Free cash flow yield
-44.24%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
83.19%
Operating margin
-433.36%
Net margin
-391.90%
Return on equity
-30.74%
Return on assets
-24.26%
Return on invested capital
-31.36%

Financial health

Debt / equity
0.13×
Current ratio
6.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends275%-424%-1124%-1823%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 95.50%Operating margin, FY2021: -1641.33%Operating margin, FY2022: 5.92%Operating margin, FY2023: -49.58%Operating margin, FY2024: -69.13%Operating margin, FY2025: -111.51%Net margin, FY2021: -1647.98%Net margin, FY2022: 4.54%Net margin, FY2023: -18.84%Net margin, FY2024: -58.49%Net margin, FY2025: -97.86%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 95.50%. Operating margin FY2021 -1641.33%. Operating margin FY2022 5.92%. Operating margin FY2023 -49.58%. Operating margin FY2024 -69.13%. Operating margin FY2025 -111.51%. Net margin FY2021 -1647.98%. Net margin FY2022 4.54%. Net margin FY2023 -18.84%. Net margin FY2024 -58.49%. Net margin FY2025 -97.86%.

Income trends

Revenue

67.22M USD-51.43%

Operating income

−74.96M USD+21.65%

Net income

−65.78M USD+18.73%
Income trends across reported periods246.7M USD82.93M USD−80.85M USD−244.62M USDRevenue, FY2021: 12.36M USDRevenue, FY2022: 205.76M USDRevenue, FY2023: 157.75M USDRevenue, FY2024: 138.39M USDRevenue, FY2025: 67.22M USDOperating income, FY2021: −202.85M USDOperating income, FY2022: 12.18M USDOperating income, FY2023: −78.21M USDOperating income, FY2024: −95.67M USDOperating income, FY2025: −74.96M USDNet income, FY2021: −203.67M USDNet income, FY2022: 9.35M USDNet income, FY2023: −29.73M USDNet income, FY2024: −80.94M USDNet income, FY2025: −65.78M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.36M USD. Revenue FY2022 205.76M USD. Revenue FY2023 157.75M USD. Revenue FY2024 138.39M USD. Revenue FY2025 67.22M USD. Operating income FY2021 −202.85M USD. Operating income FY2022 12.18M USD. Operating income FY2023 −78.21M USD. Operating income FY2024 −95.67M USD. Operating income FY2025 −74.96M USD. Net income FY2021 −203.67M USD. Net income FY2022 9.35M USD. Net income FY2023 −29.73M USD. Net income FY2024 −80.94M USD. Net income FY2025 −65.78M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue67.22M USD138.39M USD157.75M USD205.76M USD12.36M USD
Cost of goods sold3.03M USD————
Gross profit64.2M USD138.39M USD157.75M USD205.76M USD12.36M USD
Research and development112.21M USD195.16M USD192.13M USD147.75M USD173.76M USD
Selling, general, and administrative46.08M USD52.82M USD52.87M USD46.07M USD41.45M USD
Operating expenses139.15M USD234.06M USD235.95M USD193.58M USD215.21M USD
Interest income10.1M USD15.2M USD17.36M USD2.58M USD753K USD
Interest expense——767K USD3M USD2.67M USD
Depreciation and amortization3.03M USD3.54M USD2.96M USD1.53M USD1.19M USD
Operating income−74.96M USD−95.67M USD−78.21M USD12.18M USD−202.85M USD
Net income−65.78M USD−80.94M USD−29.73M USD9.35M USD−203.67M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+15.12%
11 comparable reports
Latest EPS result
-0.84
Estimate -1 · Beat by 15.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.28-0.75-1.21-1.68Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -1.11, estimate -0.33, surprise -236.36%, Miss. Q2 2025, reported May 12, 2025: actual -0.52, estimate -1.58, surprise +67.09%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.34, estimate -0.892, surprise +61.87%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.49, estimate -0.8, surprise +38.71%, Beat. Q1 2026, reported Mar 3, 2026: actual -1.03, estimate -0.92, surprise -11.96%, Miss. Q2 2026, reported May 7, 2026: actual -0.95, estimate -1.03, surprise +7.39%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.84, estimate -0.996, surprise +15.70%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.679, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates42.98M29.24M15.49M1.75MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 22.77M USD, estimate 39.95M USD, surprise -43.01%, Miss. Q2 2025, reported May 12, 2025: actual 29.38M USD, estimate 23.35M USD, surprise +25.82%, Beat. Q3 2025, reported Aug 11, 2025: actual 28.3M USD, estimate 18.83M USD, surprise +50.28%, Beat. Q4 2025, reported Nov 10, 2025: actual 17.15M USD, estimate 16.03M USD, surprise +6.97%, Beat. Q1 2026, reported Mar 3, 2026: actual 7.2M USD, estimate 15.9M USD, surprise -54.75%, Miss. Q2 2026, reported May 7, 2026: actual 2.06M USD, estimate 6.3M USD, surprise -67.26%, Miss. Q3 2026, reported Aug 6, 2026: actual 2.96M USD, estimate 3.11M USD, surprise -4.78%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.00

85.87% upside
Past 12 months12-month forecast

Price history unavailable

High $25.00Average $25.00Low $25.00

Rating distribution

21 ratings
Strong buy00%
Buy1257%
Hold524%
Sell419%
Strong sell00%

ARCT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ARCT

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
38.38M
Weight
1.85%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
7.71M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.59M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.77M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.12M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.75M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.69M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.02M
Weight
0.07%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ARCT

research.disclaimer